EP0267221A1 - Veterinary composition - Google Patents

Veterinary composition

Info

Publication number
EP0267221A1
EP0267221A1 EP19870902654 EP87902654A EP0267221A1 EP 0267221 A1 EP0267221 A1 EP 0267221A1 EP 19870902654 EP19870902654 EP 19870902654 EP 87902654 A EP87902654 A EP 87902654A EP 0267221 A1 EP0267221 A1 EP 0267221A1
Authority
EP
European Patent Office
Prior art keywords
parts
ion
composition
composition according
dextrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870902654
Other languages
German (de)
English (en)
French (fr)
Inventor
Robert James Bywater
Robert John Dupe
David Ferguson Wylie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868611343A external-priority patent/GB8611343D0/en
Priority claimed from GB868629831A external-priority patent/GB8629831D0/en
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of EP0267221A1 publication Critical patent/EP0267221A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides

Definitions

  • This invention relates to veterinary compositions useful for treating disorders in domestic animals, and in particular to compositions useful for treating shock in domestic animals and to the use of such compositions in the treatment of shock by intravenous infusion.
  • shock in domestic animals include coli mastitis in cows (which is an example of endotoxin shock), acute dehydration, such as in scouring calves, and blood loss in dogs and cats such as follows accident or injury.
  • the symptoms typically include hypovolaemia, reduced cardiac output and peripheral perfusion, and acidosis. Hypoglycaemia and hyperkalaemia may also occur.
  • Previously proposed methods of treatment nave therefore included rehydration using a large volume of liquid which is administered orally or parenterally.
  • GB-A-1,581,826 describes an oral rehydration composition for use in the treatment of scours, post-operative dehydration and stress, as well as a method of treatment which comprises administering an aqueous solution of the composition.
  • the composition comprises 40 to 80% by weight of an actively absorbed monosaccharide such as glucose, 7.5 to 30% by weight of an actively absorbed naturally occurring amino acid such as glycine, and 0.5 to 10% by weight of citric acid or a salt thereof such as tri-potassium citrate, as well as, optionally, sodium chloride and/or other ions such as bicarbonate.
  • FR-A-2,467,599 describes a rehydration composition for use in the treatment of scours which comprises an amino acid or a salt thereof such as sodium gluta ate, a sodium carboxylate such as sodium acetate, and glucose, as well as, optionally, potassium, magnesium and/or bicarbonate ions.
  • the present invention provides an aqueous veterinary composition
  • an aqueous veterinary composition comprising: not less than 300 parts sodium ion; 10 to 15 parts potassium ion; not less than 95 parts chloride ion; 200 to 400 parts bicarbonate ion and/or one or more metabolic precursors • thereof such as acetate, lactate or citrate; 0.1 to 1.0 parts magnesium ion, 5 to 15 (additional) parts citrate ion, and not more than 1000 parts dextrose, the composition having a total osmolarity of 1100 to 2400 mOsmoll"" 1 , preferably about 1600 mOsmoll" 1 .All quantities specified herein are calculated on the basis of the number of mole equivalents used.
  • the dextrose and the other solute components of the composition are stored separately in two containers as respective aqueous solutions which are mixed together immediately prior to use.
  • the two solutions will be of approximately equal osmolarity.
  • the dextrose solution will contain 500 to 1200 mmoles dextrose per 500 ml of water and the other solution to be admixed therewith will contain 610 to 1200 mmoles ions per 500 ml of water.
  • the two solutions will be mixed together, for example in approximately equal quantities, to obtain an aqueous veterinary composition according to the invention.
  • the two containers will typically oe made of a plastics material suitable for large volume intravenous infusions, such as high or low density polyethylene or plasticised PVC.
  • the containers may be rigid, semi-rigid or collapsible and may oe joined together in a suitable manner.
  • each container has two openings. One opening allows liquid filling and is sealable.
  • the other opening has a plastics/elastomeric septum closure allowing a needle to pass through, thereby enabling the contents to be withdrawn.
  • the composition will typically be administered by using a Y-piece giving set wherein the arms of the catheter have needles to empty the containers as described. The two streams of liquid thus mix in the giving set before reaching the vein during administration.
  • the invention further provides a method of treating shock in domestic animals, which method comprises administering to the animal suffering from shock a said aqueous composition intravenously.
  • the invention additionally provides a process for preparing the said aqueous composition, which process comprises mixing together the ingredients in the necessary proportions.
  • the aqueous composition of the invention will typically be prepared by mixing together a dry powder composition and water.
  • the invention still further provides a dry powder composition
  • a dry powder composition comprising: not less than 300 parts sodium ion; 10 to 15 parts potassium ion; not less than 95 parts chloride ion; 200 to 400 parts bicarbonate ion and/or one or more metabolic precursors thereof such as acetate, lactate, or citrate; 0.1 to 1.-0 parts magnesium ion, 5 to 15 (additional) parts citrate ion, and not more than 1000 parts dextrose.
  • the veterinary compositions will contain 300 to 700 parts sodium ion, 95 to 270 parts chloride ion, ana 500 to 1000 parts dextrose.
  • the veterinary compositions of the invention will typically contain at least 80, more particularly 80 to 260, parts, for example 172 parts, sodium chloride.
  • the potassium ion may be presented as potassium bicarbonate or mono-, di or tripotassiu citrate but is advantageously presented as 10 to 15 parts, more particularly aoout 13 parts, potassium chloride.
  • the citrate is preferably a sodium citrate such as trisodium citrate which may be anhydrous.
  • the veterinary composition of tne invention will additionally include up to 5 parts calcium ion, more particularly about 3 parts calcium ion, which may be presented as the chloride.
  • compositions of this invention can contain other substances such as vitamins, minerals, amino acids, excipients or the like in conventional manner.
  • the aqueous composition of the invention may include preservative agents such as bacterioci ⁇ es and/or fungicides to optimize storage life.
  • anti-bacterial agents may be administered in conjunction with the compositions of tne invention.
  • suitable anti-bacterial agents for such use include ampicillin, amoxycillin and tetracyclines.
  • the dry powder compositions of the invention may be prepared by mixing together "the individual components in conventional manner.
  • one or more of the components may be provided in anhydrous form, in order to optimize the stability of the dry powder composition. Once mixed the composition may be put into sachets or other conventional containers.
  • the aqueous compositions of the invention may be prepared by dissolving the dry powder compositions of the invention in water which preferably has been sterilized and made pyrogen-free.
  • compositions of the invention may be provided as a dry powder which can oe dissolved in water as required, as an aqueous solution which is ready for use, in the form of a twin-pack in which the dry powder is provided separately from a container of sterile water, or in the form of a twin-pack in which a dextrose solution is provided separately from a solution of the other components of the composition.
  • an aqueous solution for intravenous injection comprises at least 300, more particularly 300 to 700, mmoles sodium ion, 10 to 15 mmoles potassium ion, at least 95, more particularly 95 to 270, mmoles chloride ion, 200 to 400 mmoles bicarbonate ion and/or the precursor(s) therefor, 0.1 to 1.0 mmoles magnesium ion, 5 to 15 mmoles citrate ion and not more than 1000, more particularly 500 to 1000, mmoles dextrose per litre of water.
  • the osmolarity of such a solution is thus from 1110 to 2400mOsmoll -1 .
  • a particular advantage of the aqueous composition of the invention is that only a small volume (3 to 15 ml/kg, for example, about 0.51 for a 50 kg calf and aoout 2.51 for a 500 kg cow) need be administered, and it can be administered over a short time period. This may be followed up as required with a further dose of the aqueous composition of the invention, or with conventional fluid therapy such as the administration of isotonic saline solution.
  • the method of the invention is particularly suitable for use in the case when the animal is initially too weak to receive fluids via the oral route.
  • the method of the invention effects a rapid and effective reversal of shock, witn substantial restoration of cardiac output, peripheral perfusion and plasma volume and amelioration of hypoglycaemia and acidosis.
  • a total of 167.45g of the following composition was 5 prepared by mixing together the following ingredients in dry powder form.
  • Example 1 The effect of intravenous infusion of the aqueous solution of Example 1 was evaluated in acutely dehydrated calves.
  • the method used was to anaesthetise calves, and then place cannulas for measurement of blood pressure and central venous pressure, and volume of voided urine.
  • the calves were then made dehydrated by intravenous infusion of diuretic followed, after a period of diuresis, by intraperitoneal instillation of hypertonic mannitol solution. 4 to 5% dehydration was rapidly achieved before treatment with the aqueous solution of ExampTe 1.
  • 500ml of the solution were given by rapid intravenous infusion over about 8 minutes, and the animals were monitored for blood pressure, central venous pressure, volume of voided urine, heart rate/ECG and blood pH.Limb perfusion, blood pressure and central venous pressure were all improved, plasma volume was increased, and a low blood pH was either stabilized or improved in each subject. Limited control comparisons with 1500ml intravenous isotonic saline solution showed little improvement compared with 500ml volume of the solution of the invention. The same volume of hypertonic (1600 mOsmoll" 1 ) saline solution failed to improve the blood acid-base balance and caused high blood sodium levels.
  • Plasma volume was measured using the Evans blue dye dilution technique (Gibson and Evans J. Clin. I-nvest 1937J 16, 301-316).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19870902654 1986-05-09 1987-05-08 Veterinary composition Withdrawn EP0267221A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8611343 1986-05-09
GB868611343A GB8611343D0 (en) 1986-05-09 1986-05-09 Veterinary composition
GB868629831A GB8629831D0 (en) 1986-12-13 1986-12-13 Veterinary composition
GB8629831 1986-12-13

Publications (1)

Publication Number Publication Date
EP0267221A1 true EP0267221A1 (en) 1988-05-18

Family

ID=26290739

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19870902654 Withdrawn EP0267221A1 (en) 1986-05-09 1987-05-08 Veterinary composition
EP19870304103 Pending EP0245105A1 (en) 1986-05-09 1987-05-08 Veterinary composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19870304103 Pending EP0245105A1 (en) 1986-05-09 1987-05-08 Veterinary composition

Country Status (7)

Country Link
EP (2) EP0267221A1 (da)
JP (1) JPS63503306A (da)
AU (1) AU604708B2 (da)
DK (1) DK8188A (da)
NZ (1) NZ220230A (da)
PT (1) PT84833B (da)
WO (1) WO1987006832A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5132118A (en) * 1990-05-11 1992-07-21 Mills John A Treatment of exercise-induced pulmonary hemorrhage in animals
US5292535A (en) * 1990-06-15 1994-03-08 Regents Of The University Of California Hyperosmotic solutions for isonatremic resuscitation
GB9212737D0 (en) * 1992-06-16 1992-07-29 Norbrook Lab Veterinary product
DE19504936C1 (de) * 1995-02-15 1996-05-15 Woerwag Pharma Gmbh Arzneimittel auf der Grundlage von Magnesiumchlorid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581826A (en) * 1976-03-27 1980-12-31 Beecham Group Ltd Veterinary compositions for treating diarrhoea
AU571011B2 (en) * 1983-10-07 1988-03-31 State Of Victoria, The Treatment of neonatal calf diarrhoea
ES2038122T3 (es) * 1985-11-18 1993-07-16 Beecham Group Plc Un procedimiento para la preparacion de una composicion veterinaria2.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8706832A1 *

Also Published As

Publication number Publication date
JPS63503306A (ja) 1988-12-02
NZ220230A (en) 1990-03-27
AU604708B2 (en) 1991-01-03
AU7395287A (en) 1987-12-01
WO1987006832A1 (en) 1987-11-19
PT84833B (pt) 1990-02-08
DK8188D0 (da) 1988-01-08
DK8188A (da) 1988-01-08
PT84833A (en) 1987-06-01
EP0245105A1 (en) 1987-11-11

Similar Documents

Publication Publication Date Title
US4196196A (en) Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
KR0145289B1 (ko) 히스티딘 완충 복막 투석 용액
Rammelkamp et al. Excretion of Penicillin in Man.
US20030138501A1 (en) Bicarbonate-based solutions for dialysis therapies
Harrop et al. Studies on the Suprarenal Cortex: IV. The Effect of Sodium Salts in Sustaining the Suprarenalectomized Dog
US5112865A (en) Pharmaceutical compositions containing a derivative of 3-hydroxybutanoic acid chosen from oligomers of this acid and esters of this acid or of these oligomers with 1,3-butanediol
US5945449A (en) Sterile bicarbonate concentrate
EA003369B1 (ru) Новые фармацевтические композиции для лечения и жизнеобеспечения (поддержания жизненных функций) и способ их приготовления
Smith Supportive therapy of the toxic cow
MERRILL et al. Treatment of bromism with the artificial kidney
US4185093A (en) Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals
Groutides et al. Intravenous solutions for fluid therapy in calf diarrhoea
EP0267221A1 (en) Veterinary composition
Tremblay Intravenous fluid therapy in calves
US3548052A (en) Heparin compositions and methods of using same
Bing Etiology of Renal Failure Following Crush Injuries.
Sachs et al. Chemical and hypothermic inhibition of intravascular sludging in extracorporeal circulation
Corley Treatment of shock
Magdesian Maintenance fluid therapy in horses
Smith Fluid therapy in calves
Spier et al. Perioperative medical care for equine abdominal surgery
EP0059057A1 (en) Treatment of diarrhoea
Odunayo Fluid therapy.
RU2080110C1 (ru) Препарат для лечения острых желудочно-кишечных болезней новорожденных телят и способ его применения
Smith Fluid therapy in adult cattle.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19871223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19890731

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19910619

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WYLIE, DAVID, FERGUSON

Inventor name: DUPE, ROBERT, JOHN

Inventor name: BYWATER, ROBERT, JAMES